Phase1/-2 study of Pomalidomide in myelofibrosis

Am J Hematol. 2010 Feb;85(2):129-30. doi: 10.1002/ajh.21598.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia / drug therapy*
  • Anemia / etiology
  • Anemia / pathology
  • Anti-Inflammatory Agents / administration & dosage
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Prednisolone / administration & dosage
  • Primary Myelofibrosis / complications
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / pathology
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives*

Substances

  • Anti-Inflammatory Agents
  • Immunosuppressive Agents
  • Thalidomide
  • Prednisolone
  • pomalidomide